Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

12.6K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.6K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

3.1K
3.1K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

9.1K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.1K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

6.1K
6.1K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

8.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

2.6K
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Allostery is a widespread cause of loss-of-function variant pathogenicity.

Nature communications·2026
Same author

Seven complete comparative maps of allosteric mutations in a protein family.

Nature communications·2026
Same author

Age-dependent mutational loads in human tRNA genes are tumor-specific and result in chimeric tRNA sequences that could disrupt the genetic code.

Genome research·2026
Same author

The genetic architecture of an allosteric hormone receptor.

Nature communications·2026
Same author

Allosteric and energetic remodeling of a PDZ domain by protein domain extensions.

Nature communications·2026
Same author

The allosteric landscape of the Src kinase.

Science advances·2026

Related Experiment Video

Updated: May 2, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

26.1K

Synonymous mutations frequently act as driver mutations in human cancers.

Fran Supek1, Belén Miñana2, Juan Valcárcel3

  • 1EMBL/CRG Systems Biology Research Unit, Centre for Genomic Regulation, Dr. Aiguader 88, 08003 Barcelona, Spain; Centre for Genomic Regulation, Universitat Pompeu Fabra, Barcelona 08003, Spain.

Cell
|March 18, 2014
PubMed
Summary

Synonymous mutations, previously considered "silent," significantly contribute to human cancer by affecting gene splicing. These mutations are selected in oncogenes and tumor suppressors, impacting cancer development.

More Related Videos

In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

22.2K
Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

3.0K

Related Experiment Videos

Last Updated: May 2, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

26.1K
In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

22.2K
Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

3.0K

Area of Science:

  • Genetics
  • Cancer Biology
  • Molecular Biology

Background:

  • Synonymous mutations alter DNA sequence without changing protein sequence.
  • These mutations are often considered neutral or
  • silent
  • in their functional impact.

Purpose of the Study:

  • To investigate the role of synonymous mutations in human cancer.
  • To determine if synonymous mutations are under selection in cancer genes.
  • To explore the functional consequences of selected synonymous mutations.

Main Methods:

  • Analysis of synonymous mutations in oncogenes and tumor suppressor genes.
  • Cancer-type specific selection analysis.
  • Investigation of exonic splicing regulatory motifs.
  • Assessment of mutations in 3' untranslated regions (UTRs).

Main Results:

  • Synonymous mutations are frequently selected in human cancers, with cancer-type specificity.
  • Selected synonymous mutations often alter splicing regulatory motifs, impacting oncogene splicing.
  • Recurrent synonymous mutations in TP53 inactivate splice sites.
  • Estimated 6%-8% of selected single-nucleotide changes in oncogenes are synonymous mutations.
  • Dosage-sensitive oncogenes show selected mutations in their 3' UTRs.

Conclusions:

  • Synonymous mutations are not always silent and play a significant role in cancer development.
  • Splicing alterations driven by synonymous mutations are a key mechanism in oncogenesis.
  • The impact of synonymous mutations is context-dependent, varying between oncogenes and tumor suppressors.